Tarah J. Ballinger, MD, provides highlights on the research presented in the management of HR+/HER2- breast cancer at the 2023 San Antonio Breast Cancer Symposium. Studies such as KEYNOTE-756 and CheckMate 7FL explored immunotherapy additions to neoadjuvant chemotherapy, showcasing increased pathologic complete response rates, particularly in patients with higher PD-L1 positivity or lower estrogen-receptor expression.
Updates from the NATALEE trial demonstrated improved disease-free survival with adjuvant ribociclib, while the INAVO120 study presented promising results with the PIK3CA inhibitor inavolisib in metastatic settings, albeit with notable toxicity. Additionally, the TROPION-Breast01 trial showed improvements in progression-free survival with Dato-DXd, suggesting potential approval as another treatment option, prompting a need for strategic sequencing of therapies in patient care.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: SABCS 2023: Highlights of the Latest Advances in HR+/HER2- Breast Cancer - Medscape - Dec 13, 2023.
Comments